Evidence map›Paper›PMID 29946110›Full record

Trial reportBlood cancer journal2018

CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies.

Ayed O Ayed, Annalisa Chiappella, Levi Pederson, Betsy R Laplant, Angela Giovanna Congiu, Gianluca Gaidano, Michele Spina, Alessandro Re, Federica Cavallo, Gerardo Musuraca and 4 more

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood cancer journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ayed O AyedDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-3233-7877
Annalisa ChiappellaDivision of Hematology, Città della Salute e della Scienza Hospital and University, Torino, Italy.
Levi PedersonDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-5902-8882
Betsy R LaplantDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Angela Giovanna CongiuDepartment of Hematology, IRCCS San Martino Hospital and University, Genova, Italy.
Gianluca GaidanoDivision of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.
Michele SpinaDivision of Medical Oncology A, National Cancer Institute, Aviano, Italy.
Alessandro ReDepartment of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy.
Federica CavalloDepartment of Hematology, University of Torino, Torino, Italy.
Gerardo MusuracaDepartment of Hematology, Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori, Meldola (FC), Meldola, Italy.
William R MaconDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Thomas WitzigDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Umberto VitoloDivision of Hematology, Città della Salute e della Scienza Hospital and University, Torino, Italy.
Grzegorz S NowakowskiDivision of Hematology, Mayo Clinic, Rochester, MN, USA. Nowakowski.Grzegorz@mayo.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is a devastating event occurring in ~ 5% of patients treated with R-CHOP. We hypothesized that adding lenalidomide to R-CHOP (R2CHOP) may decrease the risk of CNS relapse. We analyzed records for patients with DLBCL from two R2CHOP trials. We assessed variables pertinent to the CNS-International Prognostic Index (CNS-IPI) scoring system and classified patients into groups of low, intermediate, and high risk of CNS relapse. The 2-year CNS relapse rate for each risk group was estimated using the Kaplan-Meier method and compared with reported rates in cohorts treated with contemporary chemoimmunotherapy. A total of 136 patients were included. Mean age was 65 and median follow-up was 48.2 months. 10.3, 71.3, and 18.4% of patients were classified into low, intermediate, and high-risk CNS-IPI groups, respectively. Only one of 136 patients developed CNS relapse, corresponding to an incidence of 0.7% and an estimated 2-year CNS relapse rate of 0.9% for the entire R2CHOP cohort. The estimated 2-year CNS relapse rates for the low, intermediate, and high-risk groups were 0, 0, and 5.0%, respectively. Frontline therapy with R2CHOP in patients with DLBCL is associated with a lower-than-expected rate of CNS relapse.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsAgedAged, 80 and overAntibodies, Monoclonal, Murine-DerivedCentral Nervous System NeoplasmsCyclophosphamideDoxorubicinFemaleHumansKaplan-Meier EstimateLenalidomideLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNeoplasm StagingPrednisoneAntibodies, Monoclonal, Murine-DerivedCyclophosphamideDoxorubicinLenalidomidePrednisoneR-CHOP protocolRituximabVincristine

Identifiers

PMID29946110
PMCPMC6018787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.